AC 150Alternative Names: AC-150
Latest Information Update: 28 Jul 2015
At a glance
- Originator Aciex Therapeutics
- Developer NicOx
- Class Antiallergics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic conjunctivitis
Most Recent Events
- 27 Oct 2014 Aciex Therapeutics has been acquired by NicOx